Abstract
AbstractThree gadolinium‐labeled compounds, potential nuclear magnetic resonance (NMR) imaging contrast agents for liver and biliary tract, were studied: 1 Gd‐DISIDA, 2( Gd‐DTPA‐Liposomes, and 3) Gd‐DTPA dihexadecylamide (Gd‐diamide). In each case, “Carrier Added” Gd‐153 with specific activity of about 5uCi/mg was used. Each labeled compound was evaluated in experimental animals. Gd‐DISIDA proved unsatisfactory because of in vivo instability. Gd‐DTPA‐Liposomes demonstrated strong toxic effects probably due to pulmonary embolism when large amounts of this compound was administered intravenously. Gd‐diamide showed good uptake in the hepatocytes with subsequent excretion into the biliary tract. Several rabbits were imaged in a 0.6T NMR imaging system before and after injection of Gd‐diamide. Pulse sequences were chosen that would yield T1‐weighted images and permit calculation of T1 relaxation times. This compound produced significant shortening of the T1 relaxation times of the liver and observable increase in intensity on the T1‐weighted images. Gd‐diamide shows promise as potential NMR contrast agent for liver and biliary tract imaging.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of Labelled Compounds and Radiopharmaceuticals
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
